SAN FRANCISCO and SUZHOU, China, Aug. 21, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that China's National Medical Products Administration (NMPA) has approved Dupert®（fulzerasib）for the treatment of adult patients with advanced non-small cell lung ...

SAN FRANCISCO and SUZHOU, China, July 25, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, today announced a strategic partnership with WeComput to jointly advance the construction and improvement of Innovent Biologics' Artificial Intelligence for Drug Discovery pla ...

SAN FRANCISCO and SUZHOU, China, July 21, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major diseases, announces that the Phase 3 clinical trial (DREAMS-1) of mazdutide (Innovent R&D code: IBI362), a glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR) dual ag ...

SAN FRANCISCO and SUZHOU, China, June 24, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major diseases, presents the key results of the first Phase 3 clinical trial of mazdutide in Chinese adults with overweight or obesity (GLORY-1) at the ADA Scientific Sessions 2024. The prima ...

SAN FRANCISCO and SUZHOU, China, June 24, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major diseases, reports the results of liver fat content from the Phase 3 study of mazdutide in Chinese adults with overweight or obesity (GLORY-1) at the ADA scientific sessions 2024.Mazduti ...

SAN FRANCISCO and SUZHOU, China, June 18, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and other major diseases, provided updates on its oncology pipeline at an investor meeting. At several major international oncology annual meetings this year, Innovent presented clinical data on multiple cancer drug cand ...

SAN FRANCISCO and SUZHOU, China, June 11, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major diseases, announces that it will present multiple clinical study results of mazdutide at the American Diabetes Association's® (ADA) 84th Scientific Sessions in Orlando from June 21 -2 ...

SAN FRANCISCO and SUZHOU, China, May 27, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today announced that picankibart (R & D code: IBI112), a recombinant anti-interleukin 23p19 subunit (IL-23p19) antibody injection, has met all the primary endpoints and key secondary endpoints in the Phase 3 re ...

转自：贝壳财经 新京报贝壳财经讯（记者张晓翀）4月19日，记者从北京市国资委获悉，北京控股首次成功发行10年期熊猫债。近日，北京控股2024年度第一期中期票据在境内银行间市场成功定价发行，发行总额20亿元人民币，期限10年，按面值平价发行，票息2.82%。订单规模达56.3亿元人民币，全场倍数2.82倍，市场反应踊跃。 本次发行是北京控股首次发行10年期熊猫债，也是银行间市场自2019年以来首笔非金融企业10年期熊猫债，创下“十年期非金融企业熊猫债最低票面利率”“银行间十年期境外主体中期票据单期最大规模”“境外主体在境内市场同期限同品种最低发行利率”“境外主体在境内市场同期限同品种单期最大规模”“境外主体在境内债券市场最长期限”“境外主体在境内市场同期限同品种最高全场倍数”多项市场纪录。 北京控股首次发行10年期熊猫债取得圆满成功，体现了资本市场对北京控股长期发展前景和优质信用的充分认可，标志着北京控股在境内债券市场初步形成了从超短到超长期债券产品相对完整的估值体系，为后续发行定价打下坚实的基础。 编辑 岳彩周 校对 吴兴发 海量资讯、精准解读，尽在新浪财经APP ...

智通财经APP讯，华控康泰(01312)发布公告，黄俞先生(黄先生)因其他工作承担已由公司执行董事调任为非执行董事，自2024年4月19日起生效。彼将同时不再担任集团行政总裁以及董事会执行委员会及董事会股份交易委员会各自的成员。 于2024年4月16日，公司收到深圳市华融泰资产管理有限公司(深圳市华融泰)的函件(提议通知)，要求根据组织章程细则尽快召开及举行公司特别股东大会，以供考虑及酌情通过决议案，以委任王飞飞先生、乔琳娜女士、郭姿秀女士及刘剑焜先生为执行董事;及委任邓丽华博士、何昊洺博士及姚小民先生为独立非执行董事，于有关普通决议案获通过后即时生效(如获通过)。 ...